Celularity

Celularity

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies.

Celuarity is a commercial stage cellular therapeutic company focusing on allogenic cellular therapies. Celularity is headquartered in Warren, New Jersey and was founded in 2016 by Carlos Ramirez, Jerome Zeldis, Jodi Gurney, John R Haines, Robert Hariri, and Steven French.

Funding
Venture round 1

On September 28, 2017 Celularity announced closing a venture round raising $40 million in capital from undisclosed investors.

Venture round 2

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins.

Timeline

February 15, 2018
Venture round 2

On February 15, 2018 Celularity completed their second round of venture funding with $250 million in capital from Colgene (lead investor), United Therapeutics, Sorrento Therapeutics, Section 32, Human Longetivity, Celgene, Bill Maris, and Tony Robbins.

September 28, 2017
Venture round 1

On September 28, 2017 Celularity announced closing a venture round raising $40 million in capital from undisclosed investors.

2016
Founding of Celularity

Celularity is headquartered in Warren, New Jersey and was founded in 2016 by Carlos Ramirez, Jerome Zeldis, Jodi Gurney, John R Haines, Robert Hariri, and Steven French.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Celularity funding round, February 2018
250,000,000
February 2018
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Celularity Announces $250M in Funding to Deliver Treatments for Cancer, Inflammatory and Degenerative Diseases, and Functional Regeneration

Celularity

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Monteverde & Associates PC
January 27, 2021
www.prnewswire.com:443
/PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS...
Celularity
January 20, 2021
www.prnewswire.com:443
/PRNewswire/ -- Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular...
Celularity
January 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Celularity Inc. ("Celularity"), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of...
December 1, 2020
BioSpace
Celularity Announces Positive DMC Safety Review and Continuation of its Phase I/II CYNK-001-COVID-19 Study - read this article along with other careers information, tips and advice on BioSpace
Celularity, Inc.
December 1, 2020
www.prnewswire.com:443
/PRNewswire/ -- Celularity announced today that the independent Data Monitoring Committee (DMC) completed the first assessment of the ongoing Phase I/II...
BioSpace
November 24, 2020
BioSpace
Celularity, Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced today that the first patient was dosed in its Phase 1 clinical study of human placental hematopoietic stem cell-derived natural killer cells (CYNK-001) in adults with r
BioSpace
November 17, 2020
BioSpace
Celularity, Inc., a clinical-stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, announced today the addition of two senior executives to its distinguished leadership team.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.